2EB0.F QUOIN PHARMACEUT.ADR5000

Healthcare Biotechnology Frankfurt Exchange
2.98 EUR
Close of Nov 11, 2026
2.80 19.30
Market cap
EUR 14.3M
P/E
-
P/B
4.28x
ROE
-527.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2EB0.F undervalued?

Graham number

The Graham number of QUOIN PHARMACEUT.ADR5000 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

QUOIN PHARMACEUT.ADR5000 fundamental analysis

No fundamental analysis for QUOIN PHARMACEUT.ADR5000 yet.

QUOIN PHARMACEUT.ADR5000 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About QUOIN PHARMACEUT.ADR5000

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, whic…

Full company profile